Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by InvestingWiseon Feb 07, 2017 7:38pm
144 Views
Post# 25813494

RE:A good new would be welcome

RE:A good new would be welcomeIndeed investor765, and sadly, this is exactly what I wrote on Saturday Feb. 4th, looking at their management report and tiny backlog for this actual Q4. Markets didn't miss it and the SP went down a little, in fact not so much (8-12%).

New contracts should be eventually announced within the next few months, but how much $$ and how many long term contracts, vs short beta testing?

Hence I'm optimistic but I've also seen other small caps failing to move upwards at this stage of early commercialization. ADK has all it needs to succeed, but it's no fairy tale (conte de fees in Fr)... Stock markets are always hungry for fast movers, and that's why ADK SP stays low for now.

Let's wait a few more months and that 0,50$ should slowly appear... Gary will have to be patient...  :-)
Bullboard Posts